MitoQ vs SS-31
Two very different ways of protecting mitochondria — an antioxidant ferried into the organelle by charge, versus a peptide that binds the structural lipid cardiolipin directly — and only one has cleared an FDA approval.
Short answer
SS-31 has FDA approval and MitoQ does not, which is the main thing separating them. SS-31 suits a reader who puts weight on FDA approval, though that approval does not cover every use it is marketed for, while MitoQ is marketed for mitochondrial antioxidant support, vascular aging and general anti-aging.
MitoQ
Mitoquinone mesylate
One real human RCT reversed vascular endothelial aging markers in healthy older adults, but the Parkinson's trial was a clean negative, and kidney-safety and exercise-redox RCTs since have also come back null — the vascular signal hasn't been shown to generalize beyond that one outcome.
Full MitoQ evidence reviewSS-31
Elamipretide
A cardiolipin-binding peptide with a mostly disappointing trial history; elamipretide won a narrow, confirmation-pending accelerated FDA approval for Barth syndrome — not for the anti-aging use it's sold for.
Full SS-31 evidence reviewMitoQ vs SS-31: head to head
- FDA status / approved use
MitoQ
Sold as a dietary supplement; no FDA approval for any indicationSS-31
FDA accelerated approval (Forzinity, 2025) for muscle strength in Barth syndrome only; investigational otherwise- Marketed for
MitoQ
Mitochondrial antioxidant support, vascular aging, general anti-agingSS-31
Mitochondrial function, longevity- Outcome areas
MitoQ
Mitochondrial / cellular energy; Cardiovascular; Longevity / lifespanSS-31
Mitochondrial / cellular energy; Longevity / lifespan- Evidence grade
MitoQ
Clinical dataSS-31
Clinical data- How it works
MitoQ
CoQ10's active form linked to a cation that pulls it into mitochondriaSS-31
Binds cardiolipin in the inner mitochondrial membrane, supporting efficient energy production- Route and dosing
MitoQ
Oral capsule, 20 mg daily in most trialsSS-31
Subcutaneous injection, 40 mg once daily- Headline human result
MitoQ
Flow-mediated dilation 42% higher vs placebo at 20 mg/day in a 2018 six-week crossover RCT of 20 older adultsSS-31
No benefit in the phase 3 MMPOWER-3 trial of 218 adults with mitochondrial myopathy; walk distance −3.2 meters vs placebo- Strongest evidence
MitoQ
Rossman 2018 vascular RCT, HypertensionMitoQ evidence reviewPubMed 29661838SS-31
Elamipretide (Barth), Genet Med 2024SS-31 evidence reviewPubMed 38602181- Key safety signal
MitoQ
No safety signal in a 12-month trial or kidney studies; untested beyond 12 monthsSS-31
No established dosing or safety profile in healthy users- How it is obtained
MitoQ
Over the counter as a dietary supplementSS-31
Prescription drug
| MitoQ | SS-31 | |
|---|---|---|
| FDA status / approved use | Sold as a dietary supplement; no FDA approval for any indication | FDA accelerated approval (Forzinity, 2025) for muscle strength in Barth syndrome only; investigational otherwise |
| Marketed for | Mitochondrial antioxidant support, vascular aging, general anti-aging | Mitochondrial function, longevity |
| Outcome areas | Mitochondrial / cellular energy; Cardiovascular; Longevity / lifespan | Mitochondrial / cellular energy; Longevity / lifespan |
| Evidence grade | Clinical data | Clinical data |
| How it works | CoQ10's active form linked to a cation that pulls it into mitochondria | Binds cardiolipin in the inner mitochondrial membrane, supporting efficient energy production |
| Route and dosing | Oral capsule, 20 mg daily in most trials | Subcutaneous injection, 40 mg once daily |
| Headline human result | Flow-mediated dilation 42% higher vs placebo at 20 mg/day in a 2018 six-week crossover RCT of 20 older adults | No benefit in the phase 3 MMPOWER-3 trial of 218 adults with mitochondrial myopathy; walk distance −3.2 meters vs placebo |
| Strongest evidence | Rossman 2018 vascular RCT, HypertensionMitoQ evidence reviewPubMed 29661838 | Elamipretide (Barth), Genet Med 2024SS-31 evidence reviewPubMed 38602181 |
| Key safety signal | No safety signal in a 12-month trial or kidney studies; untested beyond 12 months | No established dosing or safety profile in healthy users |
| How it is obtained | Over the counter as a dietary supplement | Prescription drug |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
SS-31 (elamipretide) has an actual, if narrow, FDA accelerated approval for Barth syndrome — a genetic muscle disease — pending a confirmatory trial; its broader trial history in other conditions has mostly disappointed. MitoQ has no approval anywhere and rests on one positive human vascular RCT plus a mostly null recent trial record. Different targets (antioxidant scavenging vs. structural lipid stabilization), and neither has evidence for the general anti-aging use both are marketed for.
MitoQ fits if
You want the more accessible, OTC option and are specifically interested in the vascular-aging signal from its one positive human trial.
SS-31 fits if
You're tracking mitochondria-targeted peptide drugs specifically and want the one with an actual, if narrow and confirmation-pending, FDA approval behind it.
MitoQ vs SS-31: common questions
- Is SS-31 FDA-approved but MitoQ not?
- Yes. SS-31 has FDA accelerated approval (Forzinity, 2025) for muscle strength in Barth syndrome only; investigational otherwise. MitoQ is sold as a dietary supplement; no FDA approval for any indication.
- Which has stronger human evidence, MitoQ or SS-31?
- Neither clearly. Both have human clinical data. The key source for MitoQ is Rossman 2018 vascular RCT, Hypertension; for SS-31, it is elamipretide (Barth), Genet Med 2024.
- What are the main safety concerns with MitoQ and SS-31?
- MitoQ has no safety signal in a 12-month trial or kidney studies; untested beyond 12 months. SS-31 has no established dosing or safety profile in healthy users.
Key studies behind each
MitoQ
- Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, Smith RA, Murphy MP. (2001). Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem. PubMed 11092892
- Gioscia-Ryan RA, LaRocca TJ, Sindler AL, Zigler MC, Murphy MP, Seals DR. (2014). Mitochondria-targeted antioxidant (MitoQ) ameliorates age-related arterial endothelial dysfunction in mice. J Physiol. PubMed 24665093
- Gioscia-Ryan RA, Battson ML, Cuevas LM, Eng JS, Murphy MP, Seals DR. (2018). Mitochondria-targeted antioxidant therapy with MitoQ ameliorates aortic stiffening in old mice. J Appl Physiol. PubMed 29074712
- Rossman MJ, Santos-Parker JR, Steward CAC, Bispham NZ, Cuevas LM, Rosenberg HL, Woodward KA, Chonchol M, Gioscia-Ryan RA, Murphy MP, Seals DR. (2018). Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults. Hypertension. PubMed 29661838
SS-31
- Szeto HH, Liu S. (2018). Cardiolipin-targeted peptides rejuvenate mitochondrial function, remodel mitochondria, and promote tissue regeneration during aging. Arch Biochem Biophys. PubMed 30359579
- Karaa A, Bertini E, Carelli V, Cohen BH, et al. (2023). Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. PubMed 37268435
- Karaa A, Haas R, Goldstein A, Vockley J, et al. (2018). Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. PubMed 29500292
- Reid Thompson W, Hornby B, Manuel R, Bradley E, et al. (2021). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. PubMed 33077895
The full evidence reviews
- MitoQ: the real evidence behind the mitochondria-targeted antioxidant
A genuinely engineered delivery mechanism and one well-run human vascular trial — but a Parkinson's trial and a muscle-redox trial both came back negative.
Updated August 2026
- SS-31 peptide (elamipretide): benefits, evidence and approval status
An elegant mitochondrial mechanism meets a hard clinical record: a cardiolipin-binding peptide with a failed myopathy trial and a narrow, confirmation-pending Barth syndrome approval. A straight read.
Updated October 2026